大连百傲化学股份有限公司 第四届职工代表大会第一次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 大连百傲化学股份有限公司（以下简称"公司"）于 2023 年 8 月 28 日召开第 四届职工代表大会第一次会议，会议的召集、召开及表决程序符合职工代表大会 的相关规定。经全体与会职工代表民主讨论，作出如下决议： 证券代码：603360 证券简称：百傲化学 公告编号：2023-042 （一）审议通过《关于公司<2023 年员工持股计划（草案）>及其摘要的议 案》 《大连百傲化学股份有限公司 2023 年员工持股计划（草案）》及其摘要符合 《中华人民共和国公司法》《中华人民共和国证券法》《关于上市公司实施员工持 股计划试点的指导意见》《上海证券交易所上市公司自律监管指引第 1 号——规 范运作》等相关法律法规、规范性文件及《公司章程》的规定，内容遵循依法合 规、自愿参与、风险自担的基本原则，并充分征求了公司员工的意见。公司实施 2023 年员工持股计划有助于进一步改善公司治理水平，提高员工的凝聚力和公 司竞争力，调动员 ...

证券代码：603360 证券简称：百傲化学 公告编号：2023-041 大连百傲化学股份有限公司 关于 2023 年第二季度主要经营数据的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据上海证券交易所《上市公司自律监管指引第 3 号——行业信息披露第十 三号——化工》等规定的要求，大连百傲化学股份有限公司（以下简称"公司"） 将 2023 年第二季度主要经营数据披露如下： 一、主要产品的产量、销量及收入实现情况 （一）主要产品的价格同比及环比变化幅度 | | 产品名称 | 2023 年第二季 | 2022 年第二季 | 同比增减 | 2023 年第一季 | 环比增减 | | --- | --- | --- | --- | --- | --- | --- | | | | 度平均售价 | 度平均售价 | (%) | 度平均售价 | （%） | | | | （元/千克） | （元/千克） | | （元/千克） | | | 工 | CIT/MIT 系列产品 | 15.57 | 19.86 | -21.60 | 17.03 | ...

公司于 2023 年 4 月 28 日召开的第四届董事会第十六次会议和第四届监事会 第十三次会议，审议通过了《关于回购注销 2021 年限制性股票激励计划部分限制 性股票的议案》，同意回购注销已获授但尚未解除限售的限制性股票共计 102,000 股，独立董事对此发表了同意的独立意见。具体内容详见公司于 2023 年 4 月 29 证券代码：603360 证券简称：百傲化学 公告编号：2023-036 大连百傲化学股份有限公司 关于 2021 年限制性股票激励计划 部分限制性股票回购注销实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 回购注销原因：根据大连百傲化学股份有限公司（以下简称"公司"或"本 公司"）《2021 年限制性股票激励计划（草案）（修订稿）》（以下简称"《激励 计划》"）中第十三章相关规定以及 2020 年年度股东大会的授权，鉴于公司 2021 年限制性股票激励计划中 1 名激励对象已离职，不再具备激励对象资格，公司应对 其持有的已获授但尚未解除限售的限制性股票共计 142,800 股 ...

二 二三 八 信息披露义务人声明 一、本报告书系信息披露义务人根据《中华人民共和国公司法》《中华人民 共和国证券法》《上市公司收购管理办法》《公开发行证券的公司信息披露内 容与格式准则第15号—权益变动报告书》和《公开发行证券的公司信息披露内 容与格式准则第16号—上市公司收购报告书》等相关法律、法规及规范性文件 编制。 二、根据相关法律法规的规定，本报告书已全面披露信息披露义务人在大 连百傲化学股份有限公司所拥有权益的股份变动情况。截至本报告书签署日， 除本报告书披露的持股信息外，信息披露义务人没有通过任何其他方式在大连 百傲化学股份有限公司中拥有权益。 三、信息披露义务人签署本报告书已获得必要的授权和批准，其履行亦不 违反信息披露义务人公司章程或内部规则中的任何条款，或与之相冲突。 四、本次权益变动事项尚需取得上海证券交易所合规性审查确认意见，并 在中国证券登记结算有限责任公司上海分公司办理股份过户登记手续。本次交 易尚存在一定的不确定性，提请投资者注意投资风险。 五、本次权益变动是根据本报告书所载明的资料进行的。除信息披露义务 人外，信息披露义务人没有委托或授权任何其他人提供未在本报告书中所列载 的信息 ...

证券代码：603360 证券简称：百傲化学 公告编号：2023-035 重要内容提示： 大连百傲化学股份有限公司（以下简称"百傲化学"或"公司"）股东大 连三鑫投资有限公司（以下简称"三鑫投资"或"转让方"）拟通过协议转让方 式将其持有的本公司无限售流通股 102,442,508 股股份（占目前公司总股本的 28.42%）以 11.00 元/股的价格转让给大连光曜致新舒鸿企业管理咨询合伙企业 （有限合伙）（以下简称"光曜致新"或"受让方"）。 本次权益变动属于持股 5%以上股东协议转让股份，未触及要约收购。 本次权益变动不会导致公司控股股东及实际控制人发生变化。 鉴于目前三鑫投资所持公司股份存在质押、冻结等权利限制，若无法在 交割前解除其所持股份上的权利限制，上述协议转让股份存在无法过户的风险。 本次权益变动事项尚需取得上海证券交易所合规性审查确认意见，并在 中国证券登记结算有限责任公司上海分公司办理股份转让过户登记手续，相关事 项尚存在不确定性，敬请投资者注意投资风险。 大连百傲化学股份有限公司 关于持股 5%以上股东协议转让公司股份暨权益变动 的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚 ...

大连百傲化学股份有限公司 简式权益变动报告书 上市公司名称：大连百傲化学股份有限公司 股票上市地点：上海证券交易所 股票简称：百傲化学 股票代码：603360 信息披露义务人：大连三鑫投资有限公司 注册地址：辽宁省大连市中山区五五路 47 号 1 单元 16 层 通讯地址：辽宁省大连市中山区五五路 47 号 1 单元 16 层 股份变动性质：股份减少（协议转让） 签署日期：二〇二三年八月 信息披露义务人声明 一、本报告书依据《中华人民共和国公司法》《中华人民共和国证券法》 《上市公司收购管理办法》《公开发行证券公司信息披露内容与格式准则第 15 号——权益变动报告书》及相关的法律、法规编制。 二、信息披露义务人签署本报告书已获得必要的授权和批准，其履行亦不 违反信息披露义务人章程或内部规则中的任何条款，或与之相冲突。 三、依据《中华人民共和国证券法》《上市公司收购管理办法》等规定，本 报告书已全面披露信息披露义务人在大连百傲化学股份有限公司中拥有权益的 股份变动情况。截至本报告书签署之日，除本报告书披露的信息外，上述信息 披露义务人没有通过任何其他方式增加或减少其在大连百傲化学股份有限公司 中拥有权益的股份。 ...

证券代码：603360 证券简称：百傲化学 公告编号：2023-024 大连百傲化学股份有限公司 关于召开 2022 年度业绩说明会预告公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 说明会类型 大连百傲化学股份有限公司（以下简称"公司"）已于 2023 年 04 月 29 日发 布公司 2022 年年度报告，为便于广大投资者更全面深入地了解公司 2022 年度经 营成果、财务状况，公司计划于 2023 年 06 月 15 日下午 15:00-16:30 以视频直 播结合网络文字互动形式举行 2022 年度业绩说明会，在信息披露允许的范围内 就投资者关心的问题进行交流。 二、 说明会召开的时间、地点和方式 （一）会议召开时间：2023 年 06 月 15 日 下午 15:00-16:30 （二）会议召开地点：上证路演中心（网址：http://roadshow.sseinfo.com/） （三）会议召开方式：视频直播和网络文字互动 会议召开时间：2023 年 06 月 15 日(星期四) 下午 15: ...

Financial Performance - The company's operating revenue for 2022 was CNY 1,256,659,912.76, representing a 24.88% increase compared to CNY 1,006,261,506.68 in 2021[21] - The net profit attributable to shareholders for 2022 was CNY 402,565,517.91, a 60.71% increase from CNY 250,491,543.06 in the previous year[21] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 399,418,246.97, up 57.58% from CNY 253,476,610.27 in 2021[21] - The net cash flow from operating activities for 2022 was CNY 479,900,179.76, a significant increase of 237.90% compared to CNY 142,025,131.28 in 2021[21] - Basic earnings per share increased to CNY 1.61, reflecting a growth of 61.00% compared to the previous year[22] - The diluted earnings per share rose to CNY 1.60, marking a 61.62% increase year-on-year[22] - The weighted average return on equity improved to 32.07%, an increase of 6.95 percentage points from the previous year[22] Assets and Dividends - The total assets at the end of 2022 were CNY 1,754,392,289.92, reflecting a 5.01% increase from CNY 1,670,722,296.11 at the end of 2021[21] - The net assets attributable to shareholders at the end of 2022 were CNY 1,461,271,081.01, a 39.21% increase from CNY 1,049,655,125.86 in the previous year[21] - The company plans to distribute a cash dividend of CNY 8.00 per 10 shares, totaling CNY 203,017,982.40, and issue 4 bonus shares for every 10 shares held, resulting in an increase of total shares from 258,952,000 to 360,460,991[4] Production Capacity and Market Position - The company has over 40,000 tons/year production capacity for isothiazolinone industrial biocides, making it the largest producer in Asia[31] - The company has established stable long-term partnerships with key clients such as Lanxess and Osha, enhancing its market position[31] - The company has a total production capacity of over 40,000 tons, making it the largest producer of isothiazolinone industrial biocides in Asia[34] Research and Development - Research and development expenses increased by 17.75% to CNY 47,135,682.63, reflecting the company's commitment to innovation[37] - Total R&D investment amounted to ¥47,135,682.63, representing 3.75% of operating revenue[51] - The number of R&D personnel is 70, accounting for 7.84% of the total workforce[52] Revenue Breakdown - The company's revenue from the chemical raw materials and chemical products sector reached CNY 1,253,335,619.07, with a gross profit margin of 53.10%, an increase of 6.19 percentage points year-on-year[40] - The industrial fungicide segment generated revenue of CNY 1,249,502,279.80, achieving a gross profit margin of 55.69%, which is an increase of 7.67 percentage points compared to the previous year[40] - Domestic revenue amounted to CNY 521,125,094.42, with a gross profit margin of 51.44%, while international revenue was CNY 732,210,524.65, with a gross profit margin of 54.28%[40] Environmental Compliance - The company emphasizes environmental protection and has invested in high-standard facilities to comply with stringent environmental regulations[88] - The company faces increased environmental costs due to stricter regulations, impacting profitability[89] - The company has implemented automatic monitoring systems for both wastewater and exhaust emissions, ensuring compliance with environmental regulations[146] - The company has committed to not engaging in any business activities that compete with its main operations[150] Governance and Management - The company has established a governance structure compliant with relevant laws and regulations, ensuring effective management and investor relations[92] - The company has a structured governance framework with independent directors ensuring compliance and strategic oversight[102] - The company has seen a significant management turnover, with several key personnel changes including the resignation of independent director Yuan Junjie[98] - The company appointed Dahua Accounting Firm as the financial and internal control auditor for the 2022 fiscal year, continuing a four-year relationship[156] Shareholder Information - The largest shareholder, Dalian Tongyun Investment Co., Ltd., holds 77,106,968 shares, accounting for 29.78% of the total shares[176] - Dalian Sanxin Investment Co., Ltd. holds 73,173,220 shares, representing 28.26% of the total shares[176] - The total number of ordinary shareholders as of the end of the reporting period is 13,813, an increase from 13,401 at the end of the previous month[174] Audit and Financial Reporting - The audit report confirmed that the financial statements fairly reflect the company's financial position as of December 31, 2022[194] - The management's policies and methods for revenue recognition were deemed acceptable by the auditors[196] - The company has maintained compliance with accounting standards and has no significant issues reported in the audit[196]

Financial Performance - The company's operating revenue for Q1 2023 was ¥257,856,883.15, representing a decrease of 12.31% compared to the same period last year [3] - The net profit attributable to shareholders for Q1 2023 was ¥72,655,074.26, down 26.21% year-on-year [3] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥71,804,390.36, a decline of 26.45% compared to the previous year [3] - Basic earnings per share for Q1 2023 were ¥0.29, down 25.64% from the same period last year [3] - The net profit for Q1 2023 was CNY 72,655,074.26, a decrease of 26.2% compared to CNY 98,465,601.61 in Q1 2022 [15] - Total revenue from operating activities was CNY 219,783,613.73, down 10.0% from CNY 244,334,279.59 in the same period last year [18] - The total profit before tax was CNY 83,488,195.88, down from CNY 117,134,708.98 in the previous year [15] - The company reported a total comprehensive income of CNY 71,180,490.46, down from CNY 98,464,327.84 in Q1 2022 [16] Cash Flow and Liquidity - The net cash flow from operating activities was ¥113,334,039.98, showing a slight decrease of 2.06% year-on-year [3] - Cash and cash equivalents increased to CNY 516,010,928.77 as of March 31, 2023, up from CNY 417,962,525.12 at the end of 2022, indicating improved liquidity [10] - The operating cash flow net amount was CNY 113,334,039.98, slightly down from CNY 115,713,254.47 in Q1 2022 [18] - The net cash flow from investing activities was -¥10,072,692.56, improving from -¥86,632,410.08 in Q1 2022 [26] - The net increase in cash and cash equivalents for Q1 2023 was ¥98,932,364.09, compared to a decrease of -¥36,487,878.77 in Q1 2022 [26] - The ending balance of cash and cash equivalents reached ¥494,115,594.51, significantly up from ¥173,767,264.53 in the previous year [26] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,822,250,531.34, an increase of 3.87% compared to the end of the previous year [3] - Total assets as of March 31, 2023, were CNY 1,822,250,531.34, an increase from CNY 1,754,392,289.92 at the end of 2022 [12] - Total liabilities decreased to CNY 285,987,363.08 from CNY 293,121,208.91, reflecting a reduction in financial obligations [12] - Shareholders' equity increased to CNY 1,536,263,168.26 from CNY 1,461,271,081.01, indicating growth in the company's net worth [12] - Total assets increased to CNY 1,825,185,387.46 as of March 31, 2023, up from CNY 1,757,275,735.91 at the end of 2022, representing a growth of approximately 3.8% [21] - Current assets rose to CNY 1,128,781,988.25, compared to CNY 1,050,281,587.57, marking an increase of about 7.5% [20] Shareholder Information - The top two shareholders hold significant stakes, with 大连通运投资有限公司 owning 29.78% and 大连三鑫投资有限公司 holding 28.26% of shares [6] - The company has a total of 13,401 ordinary shareholders as of the end of the reporting period [6] Research and Development - Research and development expenses were CNY 7,867,543.25, a decrease of 47.2% compared to CNY 14,891,195.96 in the previous year [15] - Research and development expenses decreased to CNY 7,867,543.25 in Q1 2023 from CNY 14,390,713.41 in Q1 2022, a reduction of approximately 45.2% [23] Future Outlook - Future outlook includes potential market expansion and new product development, although specific details were not provided in the financial report [13]

2022 年第三季度报告 证券代码：603360 证券简称：百傲化学 大连百傲化学股份有限公司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 | 项目 | 本报告期 | 本报告期比 上年同期增 | 年初至报告期末 | 年初至报告期 末比上年同期 | | --- | --- | --- | --- | --- | | | | 减变动幅度 | | 增减变动幅度 | | | | (%) | | (%) | | 营业收入 | 343,558,642.96 | 58.50 | 1,004,001,614.53 | 45.10 | ...